US pharma giant buys Germany's Celesio in $8-bn deal

US pharmaceutical distributor McKesson on Thursday announced the purchase of German rival Celesio in a deal valued at more than $8 billion.

The combined company "will be one of the largest pharmaceutical wholesalers and providers of logistics and services in the worldwide," the German firm said in a statement.

The total transaction, including McKesson's takeover of Celesio's outstanding debt is valued at approximately $8.3 billion (6.3 billion euros, the statement added.

Both firms will keep their own separate brands.

The combined firm is expected to have annual revenue of more than $150 billion, employing some 81,500 people in 20 countries worldwide.

Earlier in the month, shares in McKesson rose sharply after the Wall Street Journal reported news of the buy-out.

add to favorites email to friend print save as pdf

Related Stories

Israeli generic drug giant Teva to buy Cephalon

May 02, 2011

Teva Pharmaceutical Industries, the world's largest generic drug maker, will buy US biopharma firm Cephalon in a $6.8 billion deal, the companies said in a joint statement Monday.

US chemists Walgreens spends $6.7 bn on 45% of Boots

Jun 19, 2012

US-based Walgreens said on Tuesday was spending $6.7 billion (£4.3 billion, 5.3 billion euros) to take a 45-percent stake in European rival Alliance Boots to create the world's largest retail pharmacy chain.

German software giant SAP unveils solid Q2 profits

Jul 12, 2012

Shares in German software giant SAP soared on Thursday as it announced what it hailed as its "best-ever second quarter performance", beating analysts' expectations for operating profits.

Recommended for you

Determine patient preferences by means of conjoint analysis

19 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments